Study of Atumelnant for Cushing's Syndrome
This study is testing a new oral medication called atumelnant for people with Cushing's syndrome, a condition caused by too much cortisol. Atumelnant works by blocking the action of ACTH, a hormone that tells your body to make cortisol. Researchers want to see how safe atumelnant is and how your body handles it. You may be able to join if you are an adult with active ACTH-dependent Cushing's syndrome, including Cushing's disease or Ectopic ACTH Syndrome, and are currently taking certain other medications for it. The study will look at side effects, adrenal insufficiency (when your adrenal glands don't make enough hormones), and other lab test results to understand the drug's safety. The current status of this study is unclear, and it plans to enroll 18 participants.
- Study design
- This is an open-label study, meaning you and your doctors will know what treatment you are receiving. It's an early-stage study (Phase 1b/2a) exploring different doses of the medication.
- What's involved
- You would take oral atumelnant once daily for either 10 or 14 days. This would be followed by a monitoring period of 4 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 15 days after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
At a glance
Conditions
NCT05804669
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bethesda, Marylandno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Proportion of participants with treatment emergent adverse events (TEAEs)Up to Day 15
- Proportion of participants with adrenal insufficiencyUp to Day 15
- Proportion of participants with safety findings determined by laboratory testingUp to Day 15
- Assessment of the maximum observed plasma concentration of CRN04894Up to Day 15
- Assessment of the time to achieve maximum observed plasma concentration of CRN04894Up to Day 15
- Assessment of the plasma area under the curve of CRN04894Up to Day 15